Cytodyn Inc (CYDY)

[Saltz]

Understand enrollment was halted when Nader negotiated with FDA to lower patients from 300 to 150 to 30 for the Adjunct. Enrollment is now moving and will be completed no later than Q1 2017. We can also expect first patient injected for Mono this year. There are reasons why we are where we are. I know we lost time in terms of enrollment however moving from 300 to 30 patients was worth the wait. The path is clear now and we are going to see an acceleration in terms of enrollment for both trials. I think Nader believes when the efficacy data comes in on the Adjunct in terms of suppression of viral load it's going to turn some BP heads and especially the many people that are longing for a better solution to the current SOC. Remember that is one week after last patient injected in the AdjunctvTrial. The Mono trail will have patients beating the door down to get in. Seriously they could enroll 300 patients in The Mono Trial a month or two after the Adjunct Enrollment is completed. Things are much more positive than we know right now.